National survey for drug-resistant variants in newly diagnosed antiretroviral drug-naive patients with HIV/AIDS in South Korea: 1999-2005

J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):237-42. doi: 10.1097/QAI.0b013e318188a919.

Abstract

We investigated the prevalence of drug-resistant variants and assessed their severity against antiretroviral drugs among patients in South Korea. Three hundred antiretroviral drug-naive patients were collected and drug-resistant variants were analyzed using the Stanford database with sequences and mutation data of the HIV-1 genes for protease (codons 1-99) and reverse transcriptase (codons 1-250). Of this group, 199 isolates (66.3%) showed at least 1 or more sites related to drug resistance. However, the average prevalence of drug resistance for patients newly diagnosed with HIV-1 but still treatment-naive between 1999 and 2005 was very low (4.3%, by "SIR" interpretation) compared with other countries. Most of the newly infected patients carried HIV subtype B (96%, n = 288) based on phylogenetic analysis of the conserved pol region. In summary, there has been no significant increase in the prevalence of drug resistance among antiretroviral drug-naive patients infected with HIV-1 for the last 7 years in South Korea. This study is quite significant regarding its larger scale of prevalence study for drug-resistant variants comparing to other drug-resistant studies using small scale of populations in South Korea. It is also important to provide suitable guidelines of genotyping assays for Korean drug-naive patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / transmission
  • Acquired Immunodeficiency Syndrome / virology*
  • Adolescent
  • Adult
  • Aged
  • Anti-HIV Agents / pharmacology*
  • Drug Resistance, Viral
  • Female
  • Genotype
  • HIV-1 / classification*
  • HIV-1 / drug effects
  • HIV-1 / genetics
  • Humans
  • Korea
  • Male
  • Middle Aged
  • Phylogeny
  • Reverse Transcriptase Polymerase Chain Reaction
  • Time Factors

Substances

  • Anti-HIV Agents